Literature DB >> 18413761

Triterpenoid CDDO-methyl ester inhibits the Janus-activated kinase-1 (JAK1)-->signal transducer and activator of transcription-3 (STAT3) pathway by direct inhibition of JAK1 and STAT3.

Rehan Ahmad1, Deepak Raina, Colin Meyer, Donald Kufe.   

Abstract

The C-28 methyl ester of the oleane triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO-Me) induces apoptosis of human cancer cells by disrupting redox balance and is in clinical trials. CDDO-Me contains alpha,beta-unsaturated carbonyl groups that form reversible adducts with thiol nucleophiles. The present studies show that CDDO-Me blocks interleukin-6 (IL-6)-induced and constitutive activation of the Janus-activated kinase 1 (JAK1) in cells. In support of a direct mechanism, CDDO-Me forms adducts with JAK1 at Cys(1077) in the kinase domain and inhibits JAK1 activity. In concert with these results, CDDO-Me blocked IL-6-induced and constitutive activation of signal transducer and activator of transcription 3 (STAT3). Moreover, we show that CDDO-Me (a) binds directly to STAT3 by a mechanism dependent on the alkylation of Cys(259) and (b) inhibits the formation of STAT3 dimers. These findings indicate that CDDO-Me inhibits activation of the JAK1-->STAT3 pathway by forming adducts with both JAK1 and STAT3.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18413761      PMCID: PMC3092292          DOI: 10.1158/0008-5472.CAN-07-3036

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  46 in total

1.  Hes binding to STAT3 mediates crosstalk between Notch and JAK-STAT signalling.

Authors:  Sachiko Kamakura; Koji Oishi; Takeshi Yoshimatsu; Masato Nakafuku; Norihisa Masuyama; Yukiko Gotoh
Journal:  Nat Cell Biol       Date:  2004-05-23       Impact factor: 28.824

Review 2.  The STATs of cancer--new molecular targets come of age.

Authors:  Hua Yu; Richard Jove
Journal:  Nat Rev Cancer       Date:  2004-02       Impact factor: 60.716

3.  A STAT3 dimer formed by inter-chain disulphide bridging during oxidative stress.

Authors:  Li Li; Peter E Shaw
Journal:  Biochem Biophys Res Commun       Date:  2004-09-24       Impact factor: 3.575

4.  The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance.

Authors:  Dharminder Chauhan; Guilan Li; Klaus Podar; Teru Hideshima; Reshma Shringarpure; Laurence Catley; Constantine Mitsiades; Nikhil Munshi; Yu Tzu Tai; Nanjoo Suh; Gordon W Gribble; Tadashi Honda; Robert Schlossman; Paul Richardson; Michael B Sporn; Kenneth C Anderson
Journal:  Blood       Date:  2003-12-11       Impact factor: 22.113

5.  Requirement of matrix metalloproteinase-9 for the transformation of human mammary epithelial cells by Stat3-C.

Authors:  Tobias N Dechow; Laura Pedranzini; Andrea Leitch; Kenneth Leslie; William L Gerald; Irina Linkov; Jacqueline F Bromberg
Journal:  Proc Natl Acad Sci U S A       Date:  2004-07-12       Impact factor: 11.205

6.  The novel triterpenoid CDDO and its derivatives induce apoptosis by disruption of intracellular redox balance.

Authors:  Takashi Ikeda; Michael Sporn; Tadashi Honda; Gordon W Gribble; Donald Kufe
Journal:  Cancer Res       Date:  2003-09-01       Impact factor: 12.701

7.  Induction of redox imbalance and apoptosis in multiple myeloma cells by the novel triterpenoid 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid.

Authors:  Takashi Ikeda; Yukiko Nakata; Fumihiko Kimura; Ken Sato; Kenneth Anderson; Kazuo Motoyoshi; Michael Sporn; Donald Kufe
Journal:  Mol Cancer Ther       Date:  2004-01       Impact factor: 6.261

8.  Design, synthesis, and biological evaluation of biotin conjugates of 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid for the isolation of the protein targets.

Authors:  Tadashi Honda; Tomasz Janosik; Yukiko Honda; Jie Han; Karen T Liby; Charlotte R Williams; Robin D Couch; Amy C Anderson; Michael B Sporn; Gordon W Gribble
Journal:  J Med Chem       Date:  2004-09-23       Impact factor: 7.446

9.  Novel peptidomimetic inhibitors of signal transducer and activator of transcription 3 dimerization and biological activity.

Authors:  James Turkson; Joon S Kim; Shumin Zhang; Jing Yuan; Mei Huang; Matthew Glenn; Eric Haura; Said Sebti; Andrew D Hamilton; Richard Jove
Journal:  Mol Cancer Ther       Date:  2004-03       Impact factor: 6.261

10.  Activation of peroxisome proliferator-activated receptor gamma by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest and apoptosis in breast cancer cells.

Authors:  Helene Lapillonne; Marina Konopleva; Twee Tsao; David Gold; Teresa McQueen; Robert L Sutherland; Timothy Madden; Michael Andreeff
Journal:  Cancer Res       Date:  2003-09-15       Impact factor: 12.701

View more
  59 in total

1.  Oleanane triterpenoids in the prevention and therapy of breast cancer: current evidence and future perspectives.

Authors:  Nisha R Parikh; Animesh Mandal; Deepak Bhatia; Kodappully Sivaraman Siveen; Gautam Sethi; Anupam Bishayee
Journal:  Phytochem Rev       Date:  2014-12       Impact factor: 5.374

2.  The influence of ADAR1's regulation on lymphocyte cell function during rejection.

Authors:  Lei Cai; Yan Li; Feng Liu; Wei Zhang; Binliang Huo; Wei Zheng; Rui Ding; Jiyuan Guo; Qingchuan Zhao; Kefeng Dou
Journal:  Mol Biol Rep       Date:  2009-09-15       Impact factor: 2.316

3.  Galiellalactone is a direct inhibitor of the transcription factor STAT3 in prostate cancer cells.

Authors:  Nicholas Don-Doncow; Zilma Escobar; Martin Johansson; Sven Kjellström; Victor Garcia; Eduardo Munoz; Olov Sterner; Anders Bjartell; Rebecka Hellsten
Journal:  J Biol Chem       Date:  2014-04-22       Impact factor: 5.157

4.  Endogenous transmembrane protein UT2 inhibits pSTAT3 and suppresses hematological malignancy.

Authors:  Dongjun Lee; Ying-Hua Wang; Demetrios Kalaitzidis; Janani Ramachandran; Homare Eda; David B Sykes; Noopur Raje; David T Scadden
Journal:  J Clin Invest       Date:  2016-02-29       Impact factor: 14.808

5.  Potency ranking of triterpenoids as inducers of a cytoprotective enzyme and as inhibitors of a cellular inflammatory response via their electron affinity and their electrophilicity index.

Authors:  René V Bensasson; Vincent Zoete; Gaston Berthier; Paul Talalay; Albena T Dinkova-Kostova
Journal:  Chem Biol Interact       Date:  2010-04-28       Impact factor: 5.192

6.  Targeting Nrf2 by dihydro-CDDO-trifluoroethyl amide enhances autophagic clearance and viability of β-cells in a setting of oxidative stress.

Authors:  Wenjuan Li; Weiwei Wu; Haibo Song; Fang Wang; Huanjie Li; Li Chen; Yimu Lai; Joseph S Janicki; Keith W Ward; Colin J Meyer; Xing Li Wang; Dongqi Tang; Taixing Cui
Journal:  FEBS Lett       Date:  2014-05-08       Impact factor: 4.124

7.  TGF-β1 programmed myeloid-derived suppressor cells (MDSC) acquire immune-stimulating and tumor killing activity capable of rejecting established tumors in combination with radiotherapy.

Authors:  Padmini Jayaraman; Falguni Parikh; Jared M Newton; Aurelie Hanoteau; Charlotte Rivas; Rosemarie Krupar; Kimal Rajapakshe; Ravi Pathak; Kavin Kanthaswamy; Cassie MacLaren; Shixia Huang; Cristian Coarfa; Chad Spanos; Dean P Edwards; Robin Parihar; Andrew G Sikora
Journal:  Oncoimmunology       Date:  2018-07-26       Impact factor: 8.110

8.  Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway.

Authors:  Keinosuke Ryu; Michiro Susa; Edwin Choy; Cao Yang; Francis J Hornicek; Henry J Mankin; Zhenfeng Duan
Journal:  BMC Cancer       Date:  2010-05-10       Impact factor: 4.430

9.  The Keap1-Nrf2 system prevents onset of diabetes mellitus.

Authors:  Akira Uruno; Yuki Furusawa; Yoko Yagishita; Toshiaki Fukutomi; Hiroyuki Muramatsu; Takaaki Negishi; Akira Sugawara; Thomas W Kensler; Masayuki Yamamoto
Journal:  Mol Cell Biol       Date:  2013-05-28       Impact factor: 4.272

10.  N-acetylcysteine, reactive oxygen species and beyond.

Authors:  Shi-Yong Sun
Journal:  Cancer Biol Ther       Date:  2010-01-10       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.